GlobeNewswire

Cisco Accelerates Multicloud Journey with HyperFlex Platform Innovations

Dela

Adds support for containers and Microsoft Hyper-V, integrates multicloud services 

SAN JOSE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Cisco today announced platform innovations for Cisco® HyperFlex(TM) with the 3.0 software release that delivers performance and simplicity for any application, on any cloud, at any scale.   Enhancements include support for Microsoft Hyper-V, stretch clusters, containers, and new multicloud services that enable applications to be deployed, monitored and managed in any cloud. The result is a platform that uniquely enables development and deployment of both traditional and cloud-native applications on a common hyperconverged platform.

Cisco HyperFlex: The Power to Simplify More
Other hyperconverged solutions neglect the crucial roles that networking and distributed file systems play in the performance and scaling of clustered servers. Cisco redefined hyperconvergence with a complete end-to-end approach that engineers high performance server and networking technology, with a purpose-built filesystem. The result is industry leading performance that enables customers to efficiently support a broader array of applications, including databases and mission critical ERP workloads. 

"HyperFlex's approach enables high performance of Microsoft SQL and Oracle databases and critical applications with faster delivery of the environment, lower costs, and more effective management," said Edivaldo Rocha, CEO, CorpFlex.

The latest release of HyperFlex builds on this superior architecture and expands the opportunity for customers to simplify more.  "Customers tell us they need operational simplicity, effortless scalability, and the ability to serve the unique needs of each of their applications," said Liz Centoni, senior vice president and general manager of Cisco's Computing Systems Product Group.  "The new HyperFlex platform underscores our commitment to continuously simplify and improve data center operations and help organizations thrive in a multicloud world."

Run Any Application
The HyperFlex 3.0 software release delivers significant advancements for mission critical and cloud-native workloads:

  • Multi-hypervisor Support. In addition to VMware ESXi, HyperFlex adds hypervisor support for Microsoft Hyper-V.
  • Container Support. Data platform enhancements include a FlexVolume driver to enable persistent storage for Kubernetes managed containers, enabling development and deployment of cloud-native applications on HyperFlex.
  • Enterprise Application Validations. HyperFlex is ready for a wide range of workloads with workload profiling and sizing tools available to support application migration projects. In addition to design and deployment guides for Virtual Server Infrastructure (VSI) and Virtual Desktop Infrastructure (VDI) , Cisco design guides are now available for mission critical databases, analytics and ERP applications - including Oracle, SQL, SAP, Microsoft Exchange, and Splunk.

On Any Cloud
Organizations today require workload mobility and application monitoring across public and private clouds.  HyperFlex is the platform for the multicloud era featuring new service integrations with Cisco's multicloud software portfolio:

  • Application Performance Monitoring. AppDynamics with HyperFlex enables performance monitoring of hybrid applications running on HyperFlex and across multiple clouds.
  • Application Placement. Cisco Workload Optimization Manager (CWOM) for HyperFlex assists customers with automated analysis and workload placement.
  • Cloud Management. Introduced last year, CloudCenter for HyperFlex enables workload lifecycle management across one to many private and public clouds.
  • Private Cloud. CloudCenter for HyperFlex simplifies the deployment and management of VM's, containers and applications, making it easy for developers and administrators to consume private clouds.

At Any Scale
Only Cisco enables customers to power rapidly growing workloads with comprehensive resiliency while enjoying the global reach of cloud-based systems management.

  • Greater Scalability and Resiliency On-prem. Supporting customers with higher virtual machine density,  HyperFlex clusters now scale to 64 nodes with added resiliency through fully-automated availability zones. 
  • Stretch Clusters Across Datacenters. To meet data protection and high availability requirements, HyperFlex can now be configured into stretch clusters for campus and metro mission critical availability.
  • Cloud-based Management Across Datacenters.   Cisco Intersight now supports HyperFlex Cloud Deployment, extending simplified deployment and management to any remote location.

Applications are at the heart of digital transformation.  The changing application landscape demands support for both traditional, monolithic workloads as well as distributed microservices architectures. In addition, the ability to enable a multicloud operating environment is quickly becoming a data center requirement. According to IDC's July 2017 CloudView Survey, 85 percent of respondents are evaluating or using public cloud, while among current cloud users 87 percent have taken steps towards a hybrid cloud strategy and 94 percent plan to use multiple clouds.

Organizations are rapidly adopting hyperconverged infrastructure (HCI) to help simplify their environments.  HCI is one of the fastest growing segments in the data center space with a 5-year CAGR (2016-2021) of 30.2 percent (Source: IDC Worldwide Quarterly Converged Systems Forecast Tracker, 3CQ17).  Cisco HyperFlex is being adopted as the platform of choice for enterprise IT, accelerating this market transition with more than 2000 customers globally.

Additional Resources

About Cisco HyperFlex Systems(TM)

Cisco HyperFlex Systems delivers complete hyperconvergence, combining compute, storage, and networking resources into a simplified, easy-to-use platform. The HyperFlex data platform engineered with Cisco Unified Computing System(TM) (Cisco UCS®) delivers a dynamic data fabric(TM) with the industry-leading performance customers need to simplify more applications in their data centers. Cisco HyperFlex Systems deliver the agility, scalability, and pay-as-you-grow economics of the cloud, but with the benefits of on-premises infrastructure. Cisco HyperFlex. Simplify more. 

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

Press Relations                                                                       
Lee Davis                                                                                               
Cisco                                                                                                           
650-868-3036                                                                                                                     
leedavis@cisco.com                                                               

Analyst Relations
Jennie Olean 
Cisco
978 936-0223
jolean@cisco.com 

Investor Relations
Carol Villazon
Cisco
408-527-6538
carolv@cisco.com

Photos accompanying this announcement are available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/f62645a1-5b28-4671-ac70-24a5338e2371 http://www.globenewswire.com/NewsRoom/AttachmentNg/312438df-ca48-4c77-ac19-4664ff6f1106




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum